Article https://www.elsevier.com/tdm/userlicense/1.0/ PDF Available

Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding: An analysis of electronic health records

Journal of Thrombosis and Haemostasis · 10(4):596-605 · 2012
DOI: 10.1111/j.1538-7836.2012.04636.x
J Menzin et al.
J MenzinJ HoescheM FriedmanC NicholsG E BergmanM CrowtherD GarciaC Jones

BACKGROUND: Delayed correction of blood clotting times as measured by the International Normalized Ratio (INR) is associated with adverse outcomes among certain patients with warfarin-related major bleeding. However, there are limited data on the association between INR correction and mortality. OBJECTIVE: To assess factors associated with 30-day mortality and time to death in patients receiving fresh frozen plasma (FFP) for warfarin-associated major bleeding. METHODS: A retrospective database analysis was undertaken with electronic health record data from a large integrated health system. Patients met the following criteria: major hemorrhage diagnosis; INR ≥ 2 on the day before or day of receipt of FFP; and prescription fill for warfarin within 90 days. INR correction (defined as INR ≤ 1.3) was evaluated at the last available test 1 day following the start of FFP administration. Kaplan-Meier curves and Cox proportional hazards models were constructed to assess mortality. RESULTS: Four hundred and five patients met the selection criteria (mean age of 75 years, 54% male), and 67% remained uncorrected at 1 day following the start of FFP administration. Among all patients, 11% died within 30 days of hospital admission. An uncorrected INR was not associated with a higher risk of 30-day mortality for patients overall, but was statistically significant for the subgroup with intracranial hemorrhage (ICH) (adjusted odds ratio 2.55; 95% confidence interval 1.04-6.28). CONCLUSIONS: Among the subgroup of major bleeding patients with warfarin-associated ICH, those not correcting to either INR ≤ 1.3 or INR ≤ 1.5 with the use of FFP have an increased rate of mortality at 30 days.

Aimwell Signal Relevance AIMWELL EDITORIAL

This publication published in Journal of Thrombosis and Haemostasis represents peer-reviewed research in Aged, Aged, 80 and over, Anticoagulants directly relevant to Aimwell’s evidence intelligence infrastructure. It contributes to the FHIN network’s knowledge base on Aged and supports data-driven clinical decision making for Aimwell member organizations.

AgedAged, 80 and overAnticoagulantsBlood CoagulationBlood Component TransfusionDrug MonitoringElectronic Health RecordsFemale

Full Text

Download PDF

Source & Access

DOI / Publisher PubMed

Metrics

References19
Published2012

Source attribution: PubMed / NCBI · CrossRef

License: https://www.elsevier.com/tdm/userlicense/1.0/

Retrieved: May 21, 2026

This profile page was generated by AimwellBio based on publicly available research data. Publication content, authorship, and metadata are attributed to the original source publication.